Management of Volume Overload in Heart Failure

Heart Failure

Volumn , Issue , 2011, Pages 650-658

  Gottlieb, Stephen S ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84884420986     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4160-5895-3.10044-0     Document Type: Chapter

References (86)

1. Gottlieb S.S., Abraham W., Butler J., et al. The prognostic importance of different definitions of worsening renal function in congestive heart failure. J Card Fail 2002, 8:136-141.
2. Howard P.A., Dunn M.I. Aggressive diuresis for severe heart failure in the elderly. Chest 2001, 119:807-810.
3. Hasselblad V., Gattis Stough W., Shah M.R., et al. Relation between dose of loop diuretics and outcomes in a heart failure population: results of the ESCAPE trial. Eur J Heart Fail 2007, 9:1064-1069.
4. López B., Querejeta R., González A., et al. Effects of loop diuretics on myocardial fibrosis and collagen type I turnover in chronic heart failure. J Am Coll Cardiol 2004, 43:2028-2035.
5. Veeraveedu P.T., Watanabe K., Ma M., et al. Comparative effects of Torsemide and furosemide in rats with heart failure. Biochem Pharmacol 2008, 75:649-659.
6. Kasama S., Toyama T., Hatori T., et al. Effects of torsemide on cardiac sympathetic nerve activity and left ventricular remodelling in patients with congestive heart failure. Heart 2006, 92:1434-1440.
7. Cosín J., Díez J. TORIC investigatos. Torsemide in chronic heart failure: results of the TORIC study. Eur J Heart Fail 2002, 4:507-513.
8. Brater D.C., Day B., Burdette A., et al. Bumetanide and furosemide in heart failure. Kidney Int 1984, 26:183-189.
9. Gottlieb S.S., Khatta M., Wentworth D., et al. The effects of diuresis on the pharmacokinetics of loop diuretics in patients with heart failure. Am J Med 1998, 104:533-538.
10. Nomura A., Yasuda H., Minami M., et al. Effect of furosemide in congestive heart failure. Clin Pharmacol Ther 1981, 30:177-182.
11. Perloff J.K., Roberts W.C. The mitral apparatus: functional anatomy and mitral regurgitation. Circulation 1972, 46:227-239.
12. Ramirez A., Abelmann W.H. Hemodynamic effects of diuresis by ethacrynic acid. Arch Intern Med 1968, 121:320-326.
13. Licata G., Di Pasquale P., Parrinello G., et al. Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as bolus in refractory congestive heart failure: long-term effects. Am Heart J 2003, 145:459-466.
14. Morgan D.B., Davidson C. Hypokalemia and diuretics: an analysis of publications. BMJ 1980, 280:905-908.
15. Pitt B., Zannad F., Remme W.J., et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999, 341:709-717.
16. Brilla C.G., Matsubara L.S., Weber K.T. Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism. J Mol Cell Cardiol 1993, 25:563-575.
17. Weber K.T., Brilla C.G. Pathological hypertrophy and cardiac interstitium: fibrosis and renin-angiotensin-aldosterone system. Circulation 1991, 83:1849-1865.
18. Rocha R., Chander P.N., Khanna K., et al. Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension 1998, 31:451-458.
19. MacFayden R.J., Barr C.S., Struthers A.D. Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients. Cardiovasc Res 1997, 35:30-34.
20. Kiyingi A., Field M.J., Pawsel C.C., et al. Metolazone in treatment of severe refractory congestive heart failure. Lancet 1990, 335:29-31.
21. Binanay C., Califf R.M., Hasselblad V., et al. Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: the ESCAPE trial. JAMA 2005, 294:1625-1633.
22. Bourge R.C., Abraham W.T., Adamson P.B., et al. Randomized controlled trial of an implantable continuous hemodynamic monitor in patients with advanced heart failure: the COMPASS-HF study. J Am Coll Cardiol 2008, 51:1073-1079.
23. Tallaj J.A., Singla I., Bourge R.C. Implantable hemodynamic monitors. Heart Fail Clin 2009, 5:261-270.
24. Jourdain P., Jondeau G., Funck F., et al. Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP multicenter study. J Am Coll Cardiol 2007, 49:1733-1739.
25. Berger R., Moertl D., Peter S., et al. N-terminal pro-B-type natriuretic peptide-guided, intensive patient management in addition to multidisciplinary care in chronic heart failure: a 3-arm, prospective, randomized pilot study. J Am Coll Cardiol 2010, 55:645-653.
26. Shah K.B., Nolan M.M., Rao K., et al. The characteristics and prognostic importance of NT-ProBNP concentrations in critically ill patients. Am J Med 2007, 120:1071-1077.
27. Taylor J.A., Christenson R.H., Rao K., et al. B-type natriuretic peptide (BNP) and N-terminal pro B-type natriuretic peptide (NT-proBNP) are depressed in obesity despite higher left ventricular end diastolic pressures. Am Heart J 2006, 152:1071-1076.
28. Pelleg A., Mitamura H., Price R., et al. Extracellular potassium ion dynamics and ventricular arrhythmias in the canine heart. J Am Coll Cardiol 1989, 13:941-950.
29. Packer M., Lee W.H. Provocation of hyper- and hypokalemic sudden death during treatment with and withdrawal of converting enzyme inhibition in severe chronic congestive heart failure. Am J Cardiol 1986, 57:347-348.
30. Abraham A.S., Meshulam Z., Rosenmann D., et al. Influence of chronic diuretic therapy on serum, lymphocyte and erythrocyte potassium, magnesium and calcium concentrations. Cardiology 1988, 75:17-23.
31. Gottlieb S.S., Baruch L., Kukin M.L., et al. Prognostic importance of the serum magnesium concentrations in patients with congestive heart failure. J Am Coll Cardiol 1990, 16:827-831.
32. Anand I.S., Ferrari R., Kalra G.S., et al. Edema of cardiac origin. Studies of body water and sodium, renal function, hemodynamic indexes, and plasma hormones in untreated congestive cardiac failure. Circulation 1989, 80:299-305.
33. Schrier R.W. Water and sodium retention in edematous disorders: role of vasopressin and aldosterone. Am J Med 2006, 119(7 Suppl. 1):S47-S53.
34. Lee W.H., Packer M. Prognostic importance of serum sodium concentration and its modification by converting-enzyme inhibition in patients with severe chronic heart failure. Circulation 1986, 73:257-267.
35. Broqvist M., Dahlstrom U., Karlberg B.E., et al. Neuroendocrine response in acute heart failure and the influence of treatment. Eur Heart J 1989, 10:1075-1083.
36. Francis G.S., Benedict C., Johnstone D.E., et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure: a substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 1990, 82:1724-1729.
37. Verho M., Heintz B., Nelson K., et al. The effects of piretanide on catecholamine metabolism, plasma renin activity and plasma aldosterone: a double-blind study versus furosemide in healthy volunteers. Curr Med Res Opin 1985, 7:461-467.
38. Knight R.K., Miall P.A., Hawkins L.A., et al. Relation of plasma aldosterone concentration to diuretic treatment in patients with severe heart disease. Br Heart J 1979, 42:316-325.
39. McCurley J.M., Hanlon S.U., Wei S.K., et al. Furosemide and the progression of left ventricular dysfunction in experimental heart failure. J Am Coll Cardiol 2004, 44:1301-1307.
40. Dormans T.P., van Meyel J.J., Gerlag P.G., et al. Diuretic efficacy of high dose furosemide in severe heart failure: bolus injection versus continuous infusion. J Am Coll Cardiol 1996, 28:376-382.
41. Aaser E., Gullestad L., Tollofsrud S., et al. Effect of bolus injection versus continuous infusion of furosemide on diuresis and neurohormonal activation in patients with severe congestive heart failure. Scand J Clin Lab Invest 1997, 57:361-367.
42. Stiles, S. How to diurese in acute HF: Dosing strategies get an evidence base http://www.theheart.org/article/1058939.do. 2010 (accessed 3/23/10).
43. Multher R.S., Potter D.M., Bennett W.M. Aspirin-induced depression of glomerular filtration rate in normal humans: role of sodium balance. Ann Intern Med 1981, 94:317-321.
44. Gottlieb S.S., Robinson S., Krichten C.M., et al. Renal response to indomethacin in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 1992, 70:890-893.
45. LeJemtel T.H., Maskin C.S., Mancini D., et al. Systemic and regional hemodynamic effects of captopril and milrinone administered alone and concomitantly in patients with heart failure. Circulation 1985, 72:364-369.
46. Kanda M., Yasuda S., Goto Y., et al. Diuretic effect of phosphodiesterase inhibitors depends on baseline renal function in patients with congestive heart failure. Am J Cardiol 1999, 83:1274-1277.
47. Cuffe M.S., Califf R.M., Adams K.F., et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA 2002, 287:1541-1547.
48. Klein L., Massie B.M., Leimberger J.D., et al. For the OPTIME-CHF Investigators. Admission or changes in renal function during hospitalization for worsening heart failure predict post discharge survival: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chonic Heart Failure (OPTIME-CHF). Circ Heart Fail 2008, 1:25.
49. Varriale P., Mossavi A. The benefit of low-dose dopamine during vigorous diuresis for congestive heart failure associated with renal insufficiency: does it protect renal function?. Clin Cardiol 1997, 20:627-630.
50. Hoogenberg K., Smit A.J., Girbes A.R. Effects of low-dose dopamine on renal and systemic hemodynamics during incremental norepinephrine infusion in healthy volunteers. Crit Care Med 1998, 26:260-265.
51. Vargo D.L., Brater D.C., Rudy D.W., et al. Dopamine does not enhance furosemide-induced natriuresis in patients with congestive heart failure. J Am Soc Nephrol 1996, 7:1032-1037.
52. Kellum J.A., Decker J.M. Use of dopamine in acute renal failure: a meta-analysis. Crit Care Med 2001, 29:1526-1531.
53. Hampton J.R., van Veldhuisen D.J., Kleber F.X., et al. Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure. Second Prospective Randomised Study of Ibopamine on Mortality and Efficacy (PRIME II) Investigators. Lancet 1997, 349:971-977.
54. Lieverse A.G., van Veldhuisen D.J., Smit A.J., et al. Renal and systemic hemodynamic effects of ibopamine in patients with mild to moderate congestive heart failure. J Cardiovasc Pharmacol 1995, 25:361-367.
55. Shusterman N.H., Elliott W.J., White W.B. Fenoldopam, but not nitroprusside, improves renal function in severely hypertensive patients with impaired renal function. Am J Med 1993, 95:161-168.
56. Mathur V.S., Swan S.K., Lambrecht L.J., et al. The effects of fenoldopam, a selective dopamine receptor agonist, on systemic and renal hemodynamics in normotensive subjects. Crit Care Med 1999, 27:1832-1837.
57. Costanzo M.R., Guglin M.E., Saltzberg M.T., et al. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol 2007, 49:675-683.
58. Agostoni P., Marenzi G., Lauri G., et al. Sustained improvement in functional capacity after removal of body fluid with isolated ultrafiltration in chronic cardiac insufficiency: failure of furosemide to provide the same result. Am J Med 1994, 96:191-199.
59. Liang K.V., Hiniker A.R., Williams A.W., et al. Use of a novel ultrafiltration device as a treatment strategy for diuretic resistant, refractory heart failure: initial clinical experience in a single center. J Card Fail 2006, 12:707-714.
60. Rogers H.L., Marshall J., Bock J., et al. A randomized, controlled trial of the renal effects of ultrafiltration as compared to furosemide in patients with acute decompensated heart failure. J Card Fail 2008, 14:1-5.
61. Publication Committee for the VMAC Investigators (Vasodilatation in the Management of Acute CHF) Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA 2002, 287:1531-1540. [Erratum, JAMA 2002;288:577.].
62. Jensen K.T., Shah M.R., O'Connor C.M., et al. Renal effects of brain natriuretic peptide patients with congestive heart failure. Clin Sci 1999, 96:5-15.
63. De Zeeuw D., Janssen W.M.T., de Jong P.E. Atrial natriuretic factor: its (patho)physiological significance in humans. Kidney Int 1992, 41:1115-1133.
64. Wang D.J., Dowling T.C., Meadows D., et al. Nesiritide does not improve renal function in patients with chronic heart failure and worsening serum creatinine. Circulation 2004, 110:1620-1625.
65. Sackner-Bernstein J.D., Kowalski M., Fox M., et al. Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA 2005, 293:1900-1905.
66. Sackner-Bernstein J.D., Skopicki H.A., Aaronson K.D. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation 2005, 111:1487-1491.
67. Mitrovic V., Seferovic P.M., Simeunovic D., et al. Haemodynamic and clinical effects of ularitide in decompensated heart failure. Eur Heart J 2006, 27:2823-2832.
68. Funaya H., Kitakaze M., Node K., et al. Plasma adenosine levels increase in patients with chronic heart failure. Circulation 1997, 95:1363-1365.
69. Edlund A., Ohlsen H., Sollevi A. Renal effects of local infusion of adenosine in man. Clin Sci 1994, 87:143-149.
70. Marraccini P., Fedele S., Marzilli M., et al. Adenosine-induced renal vasoconstriction in man. Cardiovasc Res 1996, 32:949-953.
71. Schnermann J. Juxtaglomerular cell complex in the regulation of renal salt excretion. Am J Physiol 1998, 274(2 Pt 2):R263-R279.
72. 1-receptor antagonist, via pertussis toxin insensitive mechanism. J Pharmacol Exp Ther 1993, 266:200-206.
73. 1-adenosine receptor antagonist. Br J Pharmacol 1993, 109:271-277.
74. 1 receptor antagonist, on renal function and renal plasma flow in ambulatory patients with heart failure and renal impairment. J Card Fail 2007, 13:609-617.
75. 1-receptor antagonist, on diuresis and renal function in patients with acute decompensated heart failure and renal impairment or diuretic resistance. J Am Coll Cardiol 2007, 50:1551-1560.
76. Kanno K., Sasaki S., Hirata Y., et al. Urinary excretion of aquaporin-2 in patients with diabetes insipidus. N Engl J Med 1995, 332:1540-1545.
77. Goldsmith S.R., Francis G., Cowley A.W., et al. Increased plasma arginine vasopressin levels in patients with congestive heart failure. J Am Coll Cardiol 1983, 1:1385-1390.
78. 2-receptor antagonist, for hyponatremia. N Engl J Med 2006, 355:2099-2112.
79. 2 vasopressin receptor antagonist, in patients with advanced heart failure. Circulation 2001, 104:2417-2423.
80. Bosch-Marcé M., Poo J.-L., Jiménez W., et al. Comparison of two aquaretic drugs (niravoline and OPC-31260) in cirrhotic rats with ascites and water retention. J Pharmacol Exp Ther 1999, 289:194-201.
81. 2 receptor antagonist after acute and long-term treatment in rats. Eur J Pharmacol 2000, 394:131-138.
82. Gheorghiade M., Gattis W.A., O'Connor C.M., et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA 2004, 291:1963-1971.
83. 2-receptor antagonist tolvaptan and the loop diuretic furosemide in rats with heart failure. Biochem Pharmacol 2008, 75:1322-1330.
84. Gheorghiade M., Konstam M.A., Burnett J.C., et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA 2007, 297:1332-1343.
85. Konstam M.A., Gheorghiade M., Burnett J.C., et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA 2007, 297:1319-1331.
86. 1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy. Circulation 2002, 105:1348-1353.